Tvardi's IPF drug fails to meet goals in phase 2 trial
NegativeFinancial Markets

Tvardi's recent phase 2 trial for its IPF drug has not met its expected goals, raising concerns about the drug's efficacy. This outcome is significant as it could impact future development and investment in treatments for idiopathic pulmonary fibrosis, a serious lung disease. The failure of this trial may also affect patient hope for new therapies.
— Curated by the World Pulse Now AI Editorial System